Kura Oncology (KURA) Earning Somewhat Positive News Coverage, Study Shows
News headlines about Kura Oncology (NASDAQ:KURA) have been trending somewhat positive on Friday, Accern reports. Accern identifies positive and negative media coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Kura Oncology earned a coverage optimism score of 0.17 on Accern’s scale. Accern also gave headlines about the company an impact score of 47.2642887911809 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
Shares of Kura Oncology (NASDAQ KURA) opened at 7.20 on Friday. The firm has a 50-day moving average price of $8.21 and a 200-day moving average price of $8.67. The stock’s market cap is $143.91 million. Kura Oncology has a 52 week low of $4.00 and a 52 week high of $12.10.
Kura Oncology (NASDAQ:KURA) last issued its earnings results on Monday, August 7th. The company reported ($0.40) EPS for the quarter, topping the consensus estimate of ($0.43) by $0.03. On average, analysts forecast that Kura Oncology will post ($1.60) earnings per share for the current fiscal year.
Several equities research analysts recently weighed in on KURA shares. Cann restated a “buy” rating and set a $16.00 target price on shares of Kura Oncology in a research note on Monday, May 15th. Zacks Investment Research upgraded Kura Oncology from a “hold” rating to a “buy” rating and set a $10.00 target price for the company in a research note on Thursday, May 18th. Oppenheimer Holdings, Inc. set a $16.00 target price on Kura Oncology and gave the stock a “buy” rating in a research note on Wednesday, June 14th. Citigroup Inc. set a $13.00 price objective on Kura Oncology and gave the company a “buy” rating in a research note on Tuesday, August 8th. Finally, Leerink Swann reiterated an “outperform” rating and issued a $18.00 price objective (up previously from $16.00) on shares of Kura Oncology in a research note on Thursday, August 10th. Five equities research analysts have rated the stock with a buy rating, The stock presently has an average rating of “Buy” and an average price target of $14.15.
Kura Oncology Company Profile
Kura Oncology, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers.
Receive News & Ratings for Kura Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.